home / stock / ktov / ktov news

KTOV News and Press, Kitov Pharma Ltd. From 08/08/19

Stock Information
Company Name: Kitov Pharma Ltd.
Stock Symbol: KTOV
Market: NASDAQ
Menu
KTOV KTOV Quote KTOV Short KTOV News KTOV Articles KTOV Message Board
Get KTOV Alerts

News, Short Squeeze, Breakout and More Instantly...
KTOV - Kitov Pharma Reports First Half 2019 Financial Results and Provides Business Update

TEL AVIV, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced financial results for the six-month period end...
KTOV - Kitov: Q4 Becoming A Make Or Break For Investors

2019 has been a momentous year for Kitov Pharma ( KTOV ) thus far but the remaining months will be the host of a make-or-break situation for investors. Kitov is on the brink of becoming a commercial-stage company but could be delisted off the NASDAQ exchange in January of 2020. On the one hand...

KTOV - Kitov Receives Nasdaq Notification Regarding Minimum Bid Requirements

TEL AVIV, Israel, July 12, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that on July 8, 2019, the Company received...

KTOV - Kitov Successfully Completes IND-enabling Studies to advance NT219 for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancers

TEL AVIV, Israel, June 27, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class oncology therapies to overcome tumor drug resistance, increase treatment response rate, and slow tumor ...
KTOV - Kitov Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi(TM)

TEL AVIV, Israel, May 10, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class combination oncology therapies to overcome tumor drug resistance, increase treatment response rate, and slow tumor p...

KTOV - Kitov to Present Clinical Development Plan for Oncology Candidate NT-219 at the 18th MIXiii-BIOMED Conference

TEL AVIV, Israel, May 09, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (the “Company” or “Kitov”) (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class combination oncology therapies to overcome tumor drug resistance, increase treatm...

KTOV - Kitov Announces Retirement of Founder and Executive Chairman Dr. Paul Waymack

Dr. Waymack Will Continue to Serve as Kitov's Medical and Regulatory Advisor TEL AVIV, Israel, May 02, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (the “Company” or “Kitov”) (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class comb...
KTOV - Kitov's Acquisition Of FameWave Marks Transition Into Oncology

So far, 2019 has been a transformative year for Kitov Pharmaceuticals ( KTOV ) and its shareholders. The company has inked its U.S. commercialization partnership with Coeptis Pharmaceuticals for its lead product Consensi, which the company expects to launch at some point this year. Now, the co...

KTOV - Midday movers and shakers

Gainers : Fibrocell Science (NASDAQ: FCSC ) +52% . Bio-Path Holdings (NASDAQ: BPTH ) +40% . Vectrus (NYSE: VEC ) +27% . Electronics for Imaging (NASDAQ: EFII ) +27% .  SSLJ.com (NASDAQ: SSLJ ) +22% . ATA (NASDAQ: ATAI ) +21% . Advanced Disposal Services (NYSE: ADSW ) +19% . Amy...

KTOV - APHA and RBZ among premarket losers.

Reebonz Holding (NASDAQ: RBZ )  -62%  on pricing public offering. More news on: Reebonz Holding Limited, Aphria Inc., ZK International Group Co., Ltd., Stocks on the move, Read more ...

Previous 10 Next 10